Eplerenone, a new selective aldosterone blocker.


Activation of the renin-angiotensin-aldosterone system is associated with unsatisfactory outcomes in patients with hypertension and heart failure in that activation of this system is correlated strongly with both the incidence and extent of end-organ damage. Despite the availability of the angiotensin converting enzyme inhibitors (ACEi) and the angiotensin… (More)


Cite this paper

@article{McMahon2003EplerenoneAN, title={Eplerenone, a new selective aldosterone blocker.}, author={Ellen McMahon}, journal={Current pharmaceutical design}, year={2003}, volume={9 13}, pages={1065-75} }